Moderna (NASDAQ:MRNA) confirms that it is in discussions with Japan’s Ministry of Health, Labor and Welfare for the potential purchase of 40M or more doses of COVID-19 vaccine mRNA-1273.
Under the terms of the proposed agreement, it will supply the product and Takeda Pharmaceutical Co., Ltd. (NYSE:TAK) will distribute beginning in H1 2021, if the vaccine is approved.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.